RNV logo

ReNerve Limited Stock Price

ASX:RNV Community·AU$14.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

RNV Share Price Performance

AU$0.10
-0.09 (-47.37%)
AU$0.10
-0.09 (-47.37%)
Price AU$0.10

RNV Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
1 Reward

ReNerve Limited Key Details

AU$271.7k

Revenue

AU$27.0k

Cost of Revenue

AU$244.7k

Gross Profit

AU$4.0m

Other Expenses

-AU$3.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.026
90.05%
-1,374.24%
0%
View Full Analysis

About RNV

Founded
2016
Employees
n/a
CEO
Julian Chick
WebsiteView website
renerve.com.au

ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures. It develops NervAlign Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and NervAlign bionic nerve and NervAlign Nerve Graft, an off-the-shelf, ready to use nerve structure for challenging nerve repairs. The company also offers deep dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; amniotic tissue product ranges, used to aid the healing of wounds; NervAlign Nerve Conduit Range, a nerve conduit designed to facilitate nerve growth over short gaps between nerve ends; and NervAlign Nerve Guide Matrix for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting. The company was incorporated in 2016 and is headquartered in Northcote, Australia.

Recent RNV News & Updates

Recent updates

No updates